The efficacy of ASCT2 inhibition in curbing glutamine uptake has been demonstrated across various cancer types, including melanoma,[52] non‐small cell lung cancer,[53] prostate cancer,[54] and acute myeloid leukemia.[55] Kaplan‐Meier plots, coupled with the log‐rank (Mantel‐Cox) test highlighted the prognostic benefits associated with low ASCT2 expression in NSCLC (Figure S9F, Supporting Information). This evidence concerns the gene SLC1A5 and prostate cancer.